Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | acetylcholinesterase | 0.1062 | 1 | 1 |
Echinococcus granulosus | acetylcholinesterase | 0.1062 | 1 | 1 |
Echinococcus multilocularis | carboxylesterase 5A | 0.1062 | 1 | 1 |
Echinococcus granulosus | neuroligin | 0.0179 | 0.1023 | 0.1023 |
Echinococcus granulosus | acetylcholinesterase | 0.1062 | 1 | 1 |
Echinococcus multilocularis | acetylcholinesterase | 0.1062 | 1 | 1 |
Loa Loa (eye worm) | carboxylesterase | 0.1062 | 1 | 1 |
Echinococcus granulosus | nmda type glutamate receptor | 0.0086 | 0.0077 | 0.0077 |
Echinococcus granulosus | carboxylesterase 5A | 0.1062 | 1 | 1 |
Mycobacterium tuberculosis | Carboxylesterase LipT | 0.0179 | 0.1023 | 0.5 |
Echinococcus granulosus | BC026374 protein S09 family | 0.0179 | 0.1023 | 0.1023 |
Echinococcus multilocularis | glutamate (NMDA) receptor subunit | 0.0095 | 0.0168 | 0.0168 |
Brugia malayi | Carboxylesterase family protein | 0.1062 | 1 | 1 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0179 | 0.1023 | 0.0871 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.1062 | 1 | 1 |
Echinococcus granulosus | nmda type glutamate receptor | 0.0094 | 0.0151 | 0.0151 |
Loa Loa (eye worm) | hypothetical protein | 0.1062 | 1 | 1 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.0086 | 0.0077 | 0.0077 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0179 | 0.1023 | 0.0871 |
Onchocerca volvulus | 0.0179 | 0.1023 | 0.5 | |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0179 | 0.1023 | 0.0871 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.1062 | 1 | 1 |
Onchocerca volvulus | 0.0179 | 0.1023 | 0.5 | |
Mycobacterium tuberculosis | POSSIBLE PARA-NITROBENZYL ESTERASE (FRAGMENT) | 0.0179 | 0.1023 | 0.5 |
Trichomonas vaginalis | carboxylesterase domain containing protein, putative | 0.0179 | 0.1023 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.1062 | 1 | 1 |
Schistosoma mansoni | glutamate receptor NMDA | 0.0127 | 0.0485 | 0.0323 |
Echinococcus multilocularis | neuroligin | 0.0179 | 0.1023 | 0.1023 |
Echinococcus granulosus | glutamate NMDA receptor subunit | 0.0095 | 0.0168 | 0.0168 |
Echinococcus granulosus | para nitrobenzyl esterase | 0.0179 | 0.1023 | 0.1023 |
Mycobacterium tuberculosis | POSSIBLE PARA-NITROBENZYL ESTERASE (FRAGMENT) | 0.0179 | 0.1023 | 0.5 |
Schistosoma mansoni | gliotactin | 0.0179 | 0.1023 | 0.0871 |
Echinococcus multilocularis | para nitrobenzyl esterase | 0.0179 | 0.1023 | 0.1023 |
Onchocerca volvulus | 0.0179 | 0.1023 | 0.5 | |
Schistosoma mansoni | neuroligin 3 (S09 family) | 0.0179 | 0.1023 | 0.0871 |
Echinococcus multilocularis | BC026374 protein (S09 family) | 0.0179 | 0.1023 | 0.1023 |
Trichomonas vaginalis | spcc417.12 protein, putative | 0.0179 | 0.1023 | 0.5 |
Mycobacterium ulcerans | carboxylesterase, LipT | 0.0179 | 0.1023 | 0.5 |
Onchocerca volvulus | 0.0179 | 0.1023 | 0.5 | |
Echinococcus multilocularis | nmda type glutamate receptor | 0.0094 | 0.0151 | 0.0151 |
Schistosoma mansoni | acetylcholinesterase | 0.0179 | 0.1023 | 0.0871 |
Schistosoma mansoni | BC026374 protein (S09 family) | 0.0179 | 0.1023 | 0.0871 |
Echinococcus multilocularis | family S9 non peptidase ue (S09 family) | 0.0179 | 0.1023 | 0.1023 |
Onchocerca volvulus | 0.0179 | 0.1023 | 0.5 | |
Echinococcus granulosus | family S9 non peptidase ue S09 family | 0.0179 | 0.1023 | 0.1023 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
CC50 (ADMET) | = 9.4 ug ml-1 | Cytotoxicity against HEL cells assessed as reduction of growth after 3 days | ChEMBL. | 18835175 |
MCC (ADMET) | = 4 ug ml-1 | Cytotoxicity against HEL cells assessed as morphological alteration after 3 days | ChEMBL. | 18835175 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.